FDA Inspection
Hahnemann Laboratories, Inc., dba Alpine PharmaceuticalsHahnemann Laboratories, Inc., dba Alpine Pharmaceuticals – FDA Inspection, Jan 28, 2020
Record Details
This FDA Inspection record concerns Hahnemann Laboratories, Inc., dba Alpine Pharmaceuticals, with an inspection on January 28, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- January 28, 2020
- Product Type
- Drugs
View Company Profile
ID · e74fb015-6b18-4964-8744-34db101b3ed5
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1116226
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
5- 21 CFR 211.25(a)Training--operations, GMPs, written procedures
- 21 CFR 211.84(d)(2)Establish reliability of supplier"s C of A
- 21 CFR 211.84(e)Rejecting When Specifications Not Met
- 21 CFR 211.165(e)Test methods
- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Hahnemann Laboratories, Inc., dba Alpine Pharmaceuticals
3| Date | Classification | Office | Project area |
|---|---|---|---|
| January 31, 2025 | Not classified | San Francisco District Office | |
| April 27, 2017 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 25, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Hahnemann Laboratories, Inc., dba Alpine Pharmaceuticals
- FDA Inspection 1261710 - 2025-01-31
- FDA Inspection 1013205 - 2017-04-27
- FDA Inspection 716637 - 2011-03-25
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.